Panitumumab outcome by tumour location analysis
Prognosis (OS) with panitumumab + chemotherapy, by
primary tumour side
•
Boeckx N, et al. Ann Oncol 2016;27(Suppl 6):abstract 89P (and poster).
•
†
Updated values will be included in the full publication.
HR > 1 means worse prognosis in right-sided tumours.
Right-sided tumours were associated with worse prognosis
compared with left-sided tumours
WT
RAS
PRIME
(Pmab +
FOLFOX)
PEAK
(Pmab +
FOLFOX)
Study 181
(Pmab +
FOLFIRI)
Adjusted HR, right
vs left
(95% CI)
1.58
(1.02‒2.45)
NA
†
2.01
(1.29‒3.13)
